Eli Health has closed a $12 million Series A funding round led by BDC Capital’s Thrive Venture Fund to accelerate deployment of its Hormometer, the instant hormone monitoring system that delivers results from saliva to mobile app within minutes. The New York-based company has raised $20 million to date and plans to launch its platform in beta this year, beginning with cortisol monitoring. The funding will support production scaling, additional biomarker development, and expansion of the company’s personalized health platform.
Eli Health addresses a significant health gap affecting 60% of adults who experience hormone imbalance symptoms. The company focuses initially on cortisol, a stress hormone with dysregulation affecting one in three adults. Traditional lab tests miss daily hormone fluctuations, making it difficult to understand symptoms and implement appropriate lifestyle adjustments.
“Hormones regulate nearly every major system in the body—governing stress response, sleep, cognitive and physical performance, metabolism, immune function, and much more. But until now, this data has been largely invisible,” said Marina Pavlovic Rivas, Eli Health co-founder and CEO. “We’ve created the real-time interface to the human body, where hormone tracking is as easy as checking your temperature and as quick as brushing your teeth.”
The Hormometer enables users to check hormone levels instantly using saliva samples and smartphone technology, providing results alongside personal trends and AI-powered recommendations through the Eli Health app. The device requires no laboratory processing or sample shipment.
Eli Health completed more than five years of research and development, securing 12 patent-pending innovations across biochemistry, hardware, software, artificial intelligence, and endocrinology. The company has achieved FDA registration and established in-house manufacturing capabilities to meet commercial demand. The platform earned CES 2025 “Best of Innovation in Digital Health” recognition. Subscription plans begin at $8 per test with a 12-month commitment, with flexible options available.
“Hormonal health is emerging as one of the most important frontiers in personal wellness,” said Mona Minhas, Partner at BDC Thrive Venture Fund and Board Member at Eli Health. “Eli Health leveraged this shift early and, through years of focused execution, built the science, technological platform, and manufacturing infrastructure to lead the category.”
Additional investors include California-based Muse Capital, which continues serving on the company’s board, along with TELUS Global Ventures, Foreground Capital, Rocana Ventures, Accelia Capital, Garage Capital, Swizzle Ventures, IKJ Capital, Next Blue, Real Ventures, and Leva Capital.
“For the first time in history, we’ll have a continuous, real-world view of hormone patterns at scale,” said Assia Grazioli-Venier, Founding Partner at Muse Capital and Board Member at Eli Health. “That kind of insight doesn’t just improve daily health, it redefines the very infrastructure of care.”
Eli Health operates a private beta program with early adopters currently using the Hormometer for health optimization. The company also maintains a waitlist for progesterone monitoring, the next hormone planned for platform integration, and plans public launch later this year.
